Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Soleno

Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe

Soleno Therapeutics Inc. (NASDAQ:SLNO) shares fell on Friday following a short report from Scorpion Capital, which criticized the company's only product, Vykat XR, as overpriced and potentially unsafe for children with Prader-Willi syndrome (PWS).

Benzinga

3 Top Small-Cap Tech Picks for Investors This Month

Wall Street believes these three small companies have significant upside potential.

Barchart

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Soleno Concludes Type C Meeting With FDA For Diazoxide Choline In Prader-Willi Syndrome

Soleno Therapeutics Inc (NASDAQ: SLNO) said that on January 20, 2022, the Company

Benzinga

People

Tom Lee

159 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Rhythm Pharmaceuticals

30 stories

Rhythm

14 stories

Ionis Pharmaceuticals

13 stories

Ionis

12 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.